Health Care: Drugs

Valeant Pharmaceuticals International Inc (VRX: NYSE)

$255.23 -2.72 | -1.05%
07/29/15 - 04:02 PM ET
Company Cash Flow
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Cash Flow From Operating Activities
Net Income (Loss) 912.20M -863.67M -116.02M 0.00
Operating Gains/Losses -123.90M 69.37M 8.46M 5.78M
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -572.40M -261.38M -219.43M -164.58M
(Increase) Decrease in Inventories -174.30M -122.70M -80.30M -11.52M
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 188.60M -76.55M -29.07M -8.98M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 20.70M 54.68M
(Increase) Decrease In Other Working Capital 0.00 0.00 0.00 -3.63M
Other Non-Cash Items 285.40M 625.16M 314.40M 410.17M
Net Cash From Continuing Operations 2.29B 1.04B 656.58M 676.47M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 2.29B 1.04B 656.58M 676.47M
Sale of Property, Plant & Equipment 0.00 0.00 92.00M 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 53.20M 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -470.60M -184.96M -181.13M -385.95M
Acquisitions 389.70M -5.25B -3.49B -2.46B
Purchases of Short-Term Investments -72.00M 0.00 -7.20M -81.09M
Other Cash from Investing Activities 0.00 41.09M -8.87M 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -99.70M -5.38B -2.97B -2.84B
Issuance of Debt 1.65B 8.47B 6.04B 5.39B
Cash Used for Financing Activities
Issuance of Capital Stock 17.20M 10.02M 23.03M 41.74M
Repayment of Long-Term Debt -3.92B -6.40B -2.57B -2.62B
Repurchase of Capital Stock 0.00 -55.63M -280.72M -639.24M
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -196.50M 2.01B -155.61M -225.02M
Net Cash From Financing Activities -2.44B 4.03B 3.06B 1.95B
Effect of Exchange Rate Changes -29.00M -5.07M 3.76M -10.29M
Net Change in Cash & Cash Equivalents -277.70M -315.75M 751.98M -230.16M

Portfolios with VRX

Latest VRX Headlines from TheStreet

More Financial News for VRX

Press Releases for VRX

See All Press Releases

Partner Headlines for VRX

brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter